Skip to main content
Premium Trial:

Request an Annual Quote

Illumina: Stephen MacMillan, Scott Ullem

Illumina has added Hologic CEO Stephen MacMillan and Scott Ullem, CFO of Edwards Lifesciences, to its board of directors, effective immediately. MacMillan will also serve as non-executive chair of the board.

The moves come just a week after shareholders voted to replace previous chair John Thompson with Andrew Teno, a director candidate backed by dissident investor Carl Icahn. Illumina disclosed its plan to increase the size of its board near the beginning of the contested board election.

MacMillan joined Hologic in 2013 as president and CEO and was elected chair of the firm's board in 2015. Prior to that, he was CEO of Stryker. Previously, he has served on the boards of Alere, Boston Scientific, and Texas Instruments.

Ullem has been CFO at Edwards Lifesciences, a medical device firm, since 2014. Prior to that, he was CFO at Bemis Company. He spent nearly two decades in investment banking, reaching the level of managing director at Goldman Sachs and Bank of America. He also serves on the boards of Berry Global and Egnite. He holds an MBA from Harvard Business School.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.